Sign In
Buy CASI
$0.208
+0 (+0%)
At Close: May 22, 2026
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript
01:56am, Tuesday, 10'th Nov 2020
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript
Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal
02:28pm, Sunday, 01'st Nov 2020
CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint rec
CASI Pharmaceuticals Inc (CASI) Q2 2020 Earnings Call Transcript
03:30pm, Tuesday, 11'th Aug 2020
Earlier today, CASI issued a press release providing the details of our financial results for the quarter ended June 30, 2020, as well as a corporate and clinical update. The press release is availab
CASI Pharmaceuticals: Q2 Earnings Insights
11:29am, Monday, 10'th Aug 2020
Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 1.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 43.75% year over year to ($0.
CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results
11:01am, Monday, 10'th Aug 2020CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results
11:00am, Monday, 10'th Aug 2020
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial resu
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
CASI Pharmaceuticals Inc (NASDAQ:CASI) CEO Buys $5,609,609.40 in Stock
04:12am, Monday, 27'th Jul 2020
CASI Pharmaceuticals Inc (NASDAQ:CASI) CEO Wei-Wu He purchased 2,952,426 shares of the company’s stock in a transaction dated Wednesday, July 22nd. The shares were purchased at an average cost of $1
Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates
12:07pm, Sunday, 26'th Jul 2020
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Biosciences in a $540 million agreement.
CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock
01:05pm, Wednesday, 22'nd Jul 2020
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing o
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
12:00am, Wednesday, 22'nd Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 21)
ABIOMED, Inc. (NASDAQ: ABMD)
Assembly Biosciences Inc (NASDAQ: ASMB)
Bio-Rad Laboratories, Inc. (NYSE: BIO)...
CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock
08:01pm, Tuesday, 21'st Jul 2020
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has c
Here's What CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shareholder Ownership Structure Looks Like
01:39pm, Thursday, 09'th Jul 2020
A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful...
2020 Insights into the Global Multiple Myeloma Market and Competitive Landscape - ResearchAndMarkets.com
12:00am, Friday, 26'th Jun 2020
The
